LON:ONC Oncimmune (ONC) Share Price, News & Analysis GBX 15.14 +0.04 (+0.26%) (As of 10:38 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider Trades About Oncimmune Stock (LON:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncimmune alerts:Sign Up Key Stats Today's Range 15.10▼ 15.1450-Day Range 12.51▼ 2452-Week Range 9.35▼ 31Volume351,185 shsAverage Volume124,567 shsMarket Capitalization£11.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.Read More… Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesOncimmune Holdings shares tick up as notes new contractsOctober 31, 2024 | lse.co.ukUPDATE: Oncimmune raises GBP2.2 million in equity as plannedOctober 21, 2024 | lse.co.ukWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 21, 2024 | DTI (Ad)SMALL CAP MOVERS: Pulsar Helium lifted by £5m IPO fundraiseOctober 18, 2024 | msn.comCancer Biopsy Market to Reach USD 85.03 Billion by 2032, Driven by Rising Cancer Incidence and Advances in Liquid Biopsy TechnologiesOctober 9, 2024 | finance.yahoo.comOncimmune Holdings plc (ONC.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comOncimmune expects "substantial" revenue growth following contract winsSeptember 9, 2024 | lse.co.ukOncimmune Holdings agrees new contract valued at USD700,000September 2, 2024 | lse.co.ukSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncimmune's stock was trading at GBX 25.20 at the start of the year. Since then, ONC shares have decreased by 39.9% and is now trading at GBX 15.14. View the best growth stocks for 2024 here. How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($5.70) EPS for the quarter. The company had revenue of $0.08 million for the quarter. Oncimmune had a negative trailing twelve-month return on equity of 760.96% and a net margin of 586.08%. How do I buy shares of Oncimmune? Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE). Company Calendar Last Earnings2/13/2018Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ONC CUSIPN/A CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-3,140,000.00 Net Margins586.08% Pretax MarginN/A Return on Equity-760.96% Return on Assets-26.38% Debt Debt-to-Equity Ratio806.85 Current Ratio1.13 Quick Ratio0.63 Sales & Book Value Annual Sales£1.21 million Price / Sales9.28 Cash FlowGBX 1.27 per share Price / Cash Flow11.96 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares74,140,000Free FloatN/AMarket Cap£11.22 million OptionableNot Optionable Beta1.19 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (LON:ONC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.